The lobbying arms of two big U.S. law firms have jumped into the cannabis advocacy space with contracts to represent a Delaware pharmaceutical manufacturer.

Alston & Bird and Jones Walker were retained by Noramco Inc. to lobby on federal regulation of cannabidiol, or CBD, according to recent federal disclosures. Although the compound can be derived from both marijuana and hemp, it’s the non-intoxicating hemp-derived CBD that’s at the center of a booming industry producing everything from lip balms to dog treats with the additive. CBD sales are predicted to top $2.3 billion by 2022.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]